$APGE News

Truist Securities Maintains Hold on Apogee Therapeutics, Raises Price Target to $135

BTIG Downgrades Apogee Therapeutics to Neutral

Apogee Therapeutics Q2 EPS $(1.14) Misses $(1.05) Estimate

Is Apogee Therapeutics (APGE) Fully Priced, Or Still A Bargain?

What This Apogee Insider Move Might Mean After a 247% Stock Run

Apogee Therapeutics (APGE) Jumps Into Focus, Is The Stock Fully Valued?

Stifel Downgrades Apogee Therapeutics to Hold, Raises Price Target to $135

TD Cowen Downgrades Apogee Therapeutics to Hold

Guggenheim Downgrades Apogee Therapeutics to Neutral

Mizuho Downgrades Apogee Therapeutics to Neutral, Raises Price Target to $135

Deutsche Bank Downgrades Apogee Therapeutics to Hold, Raises Price Target to $135

Citigroup Downgrades Apogee Therapeutics to Neutral, Raises Price Target to $135

RBC Capital Maintains Sector Perform on Apogee Therapeutics, Raises Price Target to $135

UBS Downgrades Apogee Therapeutics to Neutral, Raises Price Target to $135.11

Wedbush Downgrades Apogee Therapeutics to Neutral, Maintains Price Target to $135

Apogee Therapeutics, Inc. (APGE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

RBC Capital Maintains Sector Perform on Apogee Therapeutics, Raises Price Target to $97

Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis Transcript

Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis - Slideshow

Apogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended Dosing